Also this week, Novartis announced it plans to make a gene-based coronavirus vaccine, which is in development at the Massachusetts Eye and Ear hospital, the Massachusetts General Hospital and the University of Pennsylvania.
The Maryland-based biotechnology company Novavax said it's launched preliminary clinical trials of its coronavirus vaccine candidate. The first results, on whether the drug is safe and effective, could be released as soon as July. The company aims to provide vaccines for those on the front lines of the COVID-19 pandemic: health care workers.
"If our phase two data support the safety and immunogenicity that we hope it will and we're able to see a signal for efficacy, it's possible that that first line would be vaccinated sometime in the fourth quarter of this year," Stanley Erck, CEO of Novavax told
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novartis to make U.S. researchers' COVID-19 gene therapy vaccine hopefulNovartis re-entered vaccine making on Thursday, inking a manufacturing deal with a U.S. team whose COVID-19 candidate relies on technology similar to that of the Swiss drugmaker's $2.1 million-per-patient gene therapy, Zolgensma. Who is hopeless? Didn't Novartis pay Michael Cohn $1million for access to DJT?
Source: Reuters - 🏆 2. / 97 Read more »
Watch Healthy Returns: The path forward with IAVI CEO Dr. Mark FeinbergCan Ebola vaccine technology be used to combat Covid-19? MegTirrell interviews Dr. Mark Feinberg about IAVI's research and partnership with Merck. megtirrell IAVI Merck Stop copyright claiming legitimate youtube channels for their own coverage of the NASA launch yesterday!!!
Source: CNBC - 🏆 12. / 72 Read more »
Moderna rally loses steam over COVID-19 vaccine worriesShares of biotechs racing to make coronavirus vaccines, including Moderna Inc , fell about 10% on Wednesday, as investor concerns grew about the prospects of the experimental products that are still in early stages of development. Guess we will have to let our immune system take care of it !!! said 97% 0f people ! Pump and Dump Cheats
Source: Reuters - 🏆 2. / 97 Read more »
Column: Developing a coronavirus vaccine should not be rushed. Here's whyHistory tells us that rushing a vaccine for COVID-19 will prove more hazardous than if it's done right. Very very frustrated that can't subscribe to LA Times from France! This. A vaccine that doesn't work, or makes people sicker, isn't a solution to our problem. We need an effective vaccine as soon as possible so those of us w/compromised immune systems can get back to work for our families. I've already been out of work since March.
Source: latimes - 🏆 11. / 82 Read more »
Novartis Inks Deal to Make Experimental Coronavirus VaccineSwiss drugmaker will make a gene-based Covid-19 vaccine being developed by researchers at Massachusetts Eye and Ear hospital, Massachusetts General Hospital and the University of Pennsylvania. OK NOW WE ARE TALKING BUSINESS, A VACCINE GENE BASED, FIGHT FIRE WITH FIRE ANY FIREFIGHTER IN THE SANTA MONICA Valley WILL TESTIFY Watch this tomorrow mate JoeyDePizza. Had it on my watch list as well. Hydroxycloroquine. It’s all we need. Thanks but no thanks
Source: WSJ - 🏆 98. / 63 Read more »
Why virus stocks are driving market volatilityOne cold, hard fact for retail investors: Vaccines have never been big moneymakers for pharmaceutical companies, and the ones that do make it to the market have historically taken between five to seven years to develop This is a fact many moderna speculators don't want to understand. Well duhh! That’s why it’s funny when Robinhood investors keep driving up vaccine makers. It had better not take that long this time or there will BE no market.
Source: MarketWatch - 🏆 3. / 97 Read more »